Article
Immunology
Roberto Scendoni, Cristina Petrelli, Mauro Giustozzi, Francesco O. Logullo
Summary: This paper presents a case of severe thrombotic complications in a 75-year-old woman after receiving the Pfizer-BioNTech COVID-19 vaccine. Laboratory tests showed no thrombophilic risk factors or thrombocytopenia in the patient. Although COVID-19 vaccines are crucial in controlling the pandemic, pharmacovigilance is still important for detecting potential multisystem thrombotic events.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
(2022)
Article
Virology
Maria Francilene Souza Silva, Ana Carolina Matias Dinelly Pinto, Fatima de Cassia Evangelista de Oliveira, Ludmilla Freire Caetano, Fernanda Montenegro de Carvalho Araujo, Marcela Helena Gambim Fonseca
Summary: This study evaluated antibody levels in individuals who had received the CoronaVac vaccine and then received a booster dose of the BNT162B2 vaccine after 6 months. The study also investigated whether a subsequent SARS-COV-2 infection would enhance the antibody response. The results showed that antibody levels peaked 30 days after the booster dose and gradually declined over time. Infection after vaccination increased antibodies against the nucleocapsid protein. The BNT162B2 vaccine boosted antibody levels against the spike protein, but the levels decreased after 60 days.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Virology
Christophe Abi Zeid Daou, Mohammad A. Natout, Nadine El Hadi
Summary: Vaccination has become a major solution in the global pandemic of COVID-19, but it is important to remain vigilant for potential side effects and life-threatening complications. Anaphylactic cases post vaccination may have a recurrence of symptoms, highlighting the need for awareness. Recognizing the potential risk of anaphylaxis in select individuals and having appropriate measures in place to deal with adverse events is crucial.
JOURNAL OF MEDICAL VIROLOGY
(2021)
Article
Biotechnology & Applied Microbiology
Roberto Scendoni, Cristina Petrelli, Giorgia Scaloni, Francesco Ottavio Logullo
Summary: Guillain-Barre syndrome (GBS) is an acute immune-mediated disease that can be triggered by infections, including after receiving COVID-19 vaccination. Clinicians must quickly recognize associated neurological complications in the ongoing mass vaccination campaign.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Article
Immunology
Rachael K. Raw, Jon Rees, Clive A. Kelly, Caroline Wroe, David R. Chadwick
Summary: A survey-based study of healthcare workers in Northeast England was conducted to investigate the influence of previous COVID-19 on vaccine-associated adverse events (AEs). The study found that AEs were worse after the first dose of the vaccine in individuals with prior COVID-19, but the second dose had greater frequency and severity of AEs regardless of COVID-19 history. Women and younger healthcare workers were more likely to report AEs after both doses, while dosing interval did not affect AEs. Ongoing symptomatic COVID-19 was associated with greater frequency and severity of AEs after the second dose. Overall, the AEs were self-limiting and short-lived in nature.
Article
Medicine, General & Internal
Amy Flaxman, Natalie G. Marchevsky, Daniel Jenkin, Jeremy Aboagye, Parvinder K. Aley, Brian Angus, Sandra Belij-Rammerstorfer, Sagida Bibi, Mustapha Bittaye, Federica Cappuccini, Paola Cicconi, Elizabeth A. Clutterbuck, Sophie Davies, Wanwisa Dejnirattisai, Christina Dold, Katie J. Ewer, Pedro M. Folegatti, Jamie Fowler, Adrian V. S. Hill, Simon Kerridge, Angela M. Minassian, Juthathip Mongkolsapaya, Yama F. Mujadidi, Emma Plested, Maheshi N. Ramasamy, Hannah Robinson, Helen Sanders, Emma Sheehan, Holly Smith, Matthew D. Snape, Rinn Song, Danielle Woods, Gavin Screaton, Sarah C. Gilbert, Merryn Voysey, Andrew J. Pollard, Teresa Lambe
Summary: The study shows that an extended interval before the second dose of the AstraZeneca vaccine leads to increased antibody titres, while a third dose significantly boosts antibody levels and enhances T-cell responses.
Article
Medicine, General & Internal
Namhee Kim, Dohsik Minn, Seungman Park, Eun Youn Roh, Jong Hyun Yoon, Hyunwoong Park, Sue Shin
Summary: An early study among Korean healthcare workers who completed the Pfizer-BioNTech COVID-19 vaccine showed that antibody titers against SARS-CoV-2 spike protein receptor binding domain increased significantly within two weeks after vaccination, with both ECLIA and LFIA tests demonstrating high sensitivity. There was no significant difference in detecting SARS-CoV-2 antibodies between whole blood and serum samples post-vaccination.
JOURNAL OF KOREAN MEDICAL SCIENCE
(2021)
Article
Multidisciplinary Sciences
Iciar Rodriguez-Avial, Cristina Garcia-Salguero, Laura Bermejo, Juan Teja, Elisa Perez-Cecilia, Alberto Delgado-Iribarren, Marta K. Vigara, Pedro K. Gil, Esther K. Culebras
Summary: This study evaluated the IgG antibody response to SARS-CoV-2 in 196 nursing home residents after the second dose of the BNT162b2 vaccine, as well as the evolution of this response over time. The impact of a third vaccine dose on immune response was also analyzed in 115 participants. The results showed that 99% of residents had a positive serological response after the second dose, and a higher response was observed in those with prior infection. The third dose increased antibody titers but did not fully restore initial levels in most cases. Overall, the vaccine demonstrated good immunogenicity in this vulnerable population.
Article
Medicine, General & Internal
Fouad Alshammari, Yacoub Abuzied, Abdulrahman Korairi, Mohammed Alajlan, Mohammed Alzomia, Mohammed AlSheef
Summary: This article describes a case of bullous fixed medication eruption following the second dose of Pfizer's COVID-19 vaccine. While common adverse effects of COVID-19 vaccines are known, such as headache and muscle soreness, little is understood about dermatological side effects.
ANNALS OF MEDICINE AND SURGERY
(2022)
Article
Immunology
Linh-An C. Tuong, Peter Capucilli, Mary Staicu, Allison Ramsey, Edward E. Walsh, S. Shahzad Mustafa
Summary: Administering the second dose of Moderna and Pfizer-BioNTech COVID-19 vaccines in a graded manner to patients with immediate hypersensitivity reactions to the first dose ensures safety and immunogenicity.
OPEN FORUM INFECTIOUS DISEASES
(2021)
Letter
Cell Biology
Luca Spiro Santovito, Graziano Pinna
Summary: The long-term and rare adverse effects of COVID-19 vaccines are currently unknown, so reporting any adverse reactions is crucial for improving the safety profile of the vaccines. In this case, acute visual impairment occurred after the second dose of the Pfizer-BioNTech vaccine.
INFLAMMATION RESEARCH
(2021)
Article
Multidisciplinary Sciences
Joao Faro-Viana, Marie-Louise Bergman, Ligia A. Goncalves, Nadia Duarte, Teresa P. Coutinho, Patricia C. Borges, Christian Diwo, Rute Castro, Paula Matoso, Vanessa Malheiro, Ana Brennand, Lindsay Kosack, Onome Akpogheneta, Joao M. Figueira, Conceicao Cardoso, Ana M. Casaca, Paula M. Alves, Telmo Nunes, Carlos Penha-Goncalves, Jocelyne Demengeot
Summary: This study analyzed the humoral immune response induced by the BNT162b2 vaccine in different age groups and found that the immunogenicity after a single dose skewed towards IgG and decreased with increasing age. The second dose of the vaccine normalized the IgG response. These findings highlight the importance of administering two doses of mRNA vaccines to achieve population-scale humoral immunity, and suggest the need for timely monitoring of elderly and immunosuppressed individuals who receive the vaccine.
NATURE COMMUNICATIONS
(2022)
Article
Immunology
Eun-Ju Kim, Seok-Ju Yoo
Summary: Cases of pulmonary embolism and deep vein thrombosis have been reported after mRNA COVID-19 vaccine (BNT162b2) administration, although the association with mRNA vaccines has not been proven, reliable studies have confirmed the link with thrombosis with thrombocytopenia syndrome (TTS), particularly for viral vector vaccines.
Article
Immunology
Vladimir Atanasov, Natalia Barreto, Jeff Whittle, John Meurer, Benjamin W. W. Weston, Qian Eric Luo, Andy Ye Yuan, Lorenzo Franchi, Ruohao Zhang, Bernard Black
Summary: Prior research shows that Pfizer and Moderna COVID-19 vaccines offer similar protection against mortality, with Pfizer having a slight advantage. However, most comparisons did not consider the selection effects of vaccine recipients. This study provides evidence of large selection effects and introduces a novel method to control for these effects. The results show that Pfizer has a higher relative mortality risk compared to Moderna for individuals aged 60 and above, but the difference is smaller and not statistically significant for booster recipients. The study also suggests the possibility of a higher vaccine dose for older individuals.
Article
Immunology
Yosuke Hirotsu, Kenji Amemiya, Hiroki Sugiura, Miyuki Shinohara, Mika Takatori, Hitoshi Mochizuki, Masao Omata
Summary: A study on healthcare workers vaccinated with the BNT162b2 mRNA vaccine found that antibody responses were significantly enhanced after the second dose in infection-naive individuals and after the first dose in previously infected individuals. The robust boosting effect of immunization suggests that increased antibody titres following exposure to the virus may limit viral replication, prolong the incubation period, or reduce the severity of the disease.
FRONTIERS IN IMMUNOLOGY
(2021)